https://www.fool.com/investing/2018/01/18/healthcare-is-celgene-going-to-buy-juno-therapeuti.aspx
Healthcare: Is Celgene Going to Buy Juno Therapeutics? | The Motley Fool
Jan 18, 2018 - A big biotech merger could be in the works.
going tojuno therapeuticshealthcarecelgene
https://www.prnewswire.com/news-releases/critical-alerts-for-juno-therapeutics-inc-broadcom-eli-lilly-esperion-therapeutics-and-world-wrestling-entertainment-released-by-investorsobserver-300089825.html
Critical Alerts For Juno Therapeutics Inc, Broadcom, Eli Lilly, Esperion Therapeutics and World...
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JUNO, BRCM, LLY, ESPR and WWE. To see what our analysts have discovered about a...
juno therapeutics
https://www.fool.com/investing/general/2015/10/06/why-juno-therapeutics-jumped-today.aspx
Why Juno Therapeutics Jumped Today | The Motley Fool
Oct 6, 2015 - Investors are giddy about the biotech's prospects.
juno therapeuticsjumpedtodaymotleyfool
https://www.pharmaceutical-technology.com/projects/juno-therapeutics-headquarters-rd-facility-washington/
Juno Therapeutics Headquarters and R&D Facility, Washington
juno therapeuticsheadquartersfacilitywashington
https://www.fiercebiotech.com/keyword/juno-therapeutics
Juno Therapeutics | Fierce Biotech
juno therapeuticsfiercebiotech
https://www.fool.com/investing/2017/03/01/juno-therapeutics-q4-financial-results-overshadowe.aspx
Juno Therapeutics' Q4 Financial Results Overshadowed by Pipeline Setback | The Motley Fool
Mar 1, 2017 - The clinical-stage biotech reported higher quarterly revenue thanks to its collaboration with Celgene. But its move to halt development of its lead drug...
juno therapeuticsfinancial results
https://www.biospace.com/juno-therapeutics-post-ipo-ups-and-downs-but-mostly-ups
Juno Therapeutics Post IPO: Ups and Downs But Mostly Ups - BioSpace
ups and downsjuno therapeuticspostipomostly
https://www.fool.com/investing/2016/09/27/heres-why-juno-therapeutics-is-shooting-higher-tod.aspx
Here's Why Juno Therapeutics Is Shooting 10% Higher Today | The Motley Fool
Sep 27, 2016 - Positive trial results from Kite Pharma are rekindling interest in Juno Therapeutics' CAR-T research program.
https://www.biospace.com/juno-therapeutics-to-present-at-the-bank-of-america-merrill-lynch-2015-health-care-conference
Juno Therapeutics To Present At The Bank of America Merrill Lynch 2015 Health Care Conference -...
bank of america merrill lynch
https://www.biospace.com/juno-therapeutics-to-report-first-quarter-2015-financial-results-on-monday-may-11
Juno Therapeutics To Report First Quarter 2015 Financial Results On Monday, May 11 - BioSpace
https://www.bakermckenzie.com/en/newsroom/2025/06/bristol-myers-squibb
Baker McKenzie Advised Bristol Myers Squibb on the Transfer of Juno Therapeutics GmbH to TQ...
Baker McKenzie has advised Bristol Myers Squibb on the transfer of Juno Therapeutics GmbH to TQ Therapeutics GmbH through a share acquisition ...
https://stockhouse.com/news/press-releases/2016/07/07/juno-therapeutics-plunges-30-after-2-patient-deaths-from-lead-cancer-drug
2016-07-07 | Juno Therapeutics Plunges 30% After 2 Patient Deaths From Lead Cancer Drug | ARCA:XBI...
(2016-07-07 | ARCA:XBI) Juno Therapeutics Plunges 30% After 2 Patient Deaths From Lead Cancer Drug